Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
Lyell Immunopharma reported that gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea or colitis in LYL273 patients from 55% to 10%, with no Grade 3+ CRS or ICANS observed in the prophylaxis group. The company amended its U.S. Phase 1 trial to a Phase 1/2 design (CARABINER), enabling seamless expansion into a potential pivotal single-arm Phase 2 trial pending FDA alignment.
Key figures
- Drug Name
- LYL273
- Phase Of Trial
- Phase 1
- Patients enrolled phase 1
- 19
- Patients with prophylaxis
- 10
- Patients without prophylaxis
- 9
- Overall response rate 3l plus
- 50%
- Grade 2 plus diarrhea with prophylaxis
- 10%
- Grade 2 plus diarrhea without prophylaxis
- 55%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.